<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6035">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01067781</url>
  </required_header>
  <id_info>
    <org_study_id>ELT208</org_study_id>
    <nct_id>NCT01067781</nct_id>
  </id_info>
  <brief_title>Gender-Stratified Safety and Immunogenicity Study</brief_title>
  <official_title>A Phase 2, Gender-Stratified, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Two Vaccination Regimen With the Travelers' Diarrhea Vaccine System in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercell USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercell USA, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare the safety and immune responses
      following a two vaccination regimen by transcutaneous immunization with heat-labile
      enterotoxin of E. coli (LT) patches or placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Characterization and Comparison of the Safety of the TD Vaccine System: (1) Solicited and Unsolicited Adverse Events (AEs) (2) Clinical Laboratory Safety (3) Serious AEs</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Erythema, rash, pain, pruritus, hyperpigmentation, hypopigmentation and edema were solicited local AEs for the duration of the study. Fever, malaise, headache, and diarrhea were solicited systemic AEs for the first seven days following each vaccination; events reported outside this time frame were considered non-solicited.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization and Comparison of Group LT-specific Immune Responses to the TD Vaccine System: (1) Geometric Mean Titers (2) Geometric Mean Fold Ratios (3) Seroconversion Rates</measure>
    <time_frame>Day 0 to Day 180</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two vaccination regimen with an LT patch (no swabbing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two vaccination regimen with an LT patch (with swabbing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two vaccination regimen with a placebo patch (no swabbing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two vaccination regimen with a placebo patch (with swabbing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Heat-Labile Enterotoxin of E. coli (LT)</intervention_name>
    <description>Travelers' Diarrhea Vaccine System</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Travelers' Diarrhea Vaccine System</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A female or male 18-64 (inclusive) years of age;

          2. In good health as determined by medical history and screening exam;

          3. Females who are post-menopausal, surgically sterile, or have a negative serum/urine
             pregnancy test at Day 0 and agree not to become pregnant for the duration of study.

        Exclusion Criteria:

          1. Abnormalities at physical exam [as determined by the Toxicity Grading Scale (Grade
             1-4)];

          2. Laboratory abnormalities [as determined by the Toxicity Grading Scale (Grade 1 4)] at
             screening;

          3. Participated in research involving investigational product within 30 days before
             planned date of first vaccination;

          4. Ever received investigational enterotoxigenic E. coli, LT, or LT (R192G) or NasalFlu,
             Berna Biotech, Ltd;

          5. Women who are pregnant or breastfeeding;

          6. Clinically significant underlying enteric, pulmonary, cardiac or renal disease;

          7. Current seizure disorder;

          8. Current use of immunosuppressive therapy (inhaled steroids are allowed);

          9. Known or suspected alcohol abuse or illicit drug use within the last year;

         10. Positive Serology for HIV-1, HIV-2, HbsAg, or HCV;

         11. Known allergies to any component of the vaccine including adhesives;

         12. An employee of the study site;

         13. An employee of Intercell (global) or an immediate family member;

         14. Visible tattoos or marks (tattoos/scars) at the vaccination areas that would prevent
             appropriate dermatologic monitoring of the vaccination sites;

         15. Receipt of any routine vaccinations within 7 days prior to, or following, the date of
             planned study vaccinations.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Sheldon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miami Research Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clinical Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.intercell.com</url>
    <description>Intercell Home Page</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>February 9, 2010</firstreceived_date>
  <firstreceived_results_date>January 30, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention of Travelers' Diarrhea</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: 37.5μg LT, No Swab</title>
          <description>Two vaccination regimen with an LT patch (no swabbing)
Heat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System</description>
        </group>
        <group group_id="P2">
          <title>Group 2: 37.5μg LT, Swab</title>
          <description>Two vaccination regimen with an LT patch (with swabbing)
Heat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System</description>
        </group>
        <group group_id="P3">
          <title>Group 3: 0μg LT, No Swab</title>
          <description>Two vaccination regimen with a placebo patch (no swabbing)
Placebo: Travelers' Diarrhea Vaccine System</description>
        </group>
        <group group_id="P4">
          <title>Group 4: 0μg LT, Swab</title>
          <description>Two vaccination regimen with a placebo patch (with swabbing)
Placebo: Travelers' Diarrhea Vaccine System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Up to Day 180</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="199"/>
                <participants group_id="P3" count="97"/>
                <participants group_id="P4" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="89"/>
                <participants group_id="P4" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Up to Day 720</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="199"/>
                <participants group_id="P3" count="97"/>
                <participants group_id="P4" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3">all subects followed till Day180; if ongoing local AE, FU every 6 mths till AE resolved (max.Day720)</participants>
                <participants group_id="P2" count="4">all subects followed till Day180; if ongoing local AE, FU every 6 mths till AE resolved (max.Day720)</participants>
                <participants group_id="P3" count="0">all subects followed till Day180; if ongoing local AE, FU every 6 mths till AE resolved (max.Day720)</participants>
                <participants group_id="P4" count="0">all subects followed till Day180; if ongoing local AE, FU every 6 mths till AE resolved (max.Day720)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="195"/>
                <participants group_id="P3" count="97"/>
                <participants group_id="P4" count="101"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>safety population: includes all study subjects that were consented and received investigational study material (i.e., at least one vaccination)</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: 37.5μg LT, No Swab</title>
          <description>Two vaccination regimen with an LT patch (no swabbing)
Heat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System</description>
        </group>
        <group group_id="B2">
          <title>Group 2: 37.5μg LT, Swab</title>
          <description>Two vaccination regimen with an LT patch (with swabbing)
Heat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System</description>
        </group>
        <group group_id="B3">
          <title>Group 3: 0μg LT, No Swab</title>
          <description>Two vaccination regimen with a placebo patch (no swabbing)
Placebo: Travelers' Diarrhea Vaccine System</description>
        </group>
        <group group_id="B4">
          <title>Group 4: 0μg LT, Swab</title>
          <description>Two vaccination regimen with a placebo patch (with swabbing)
Placebo: Travelers' Diarrhea Vaccine System</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="203"/>
                <measurement group_id="B2" value="199"/>
                <measurement group_id="B3" value="97"/>
                <measurement group_id="B4" value="101"/>
                <measurement group_id="B5" value="600"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="36.0" spread="12.8"/>
                <measurement group_id="B2" value="35.3" spread="13.1"/>
                <measurement group_id="B3" value="35.0" spread="13.6"/>
                <measurement group_id="B4" value="35.7" spread="12.8"/>
                <measurement group_id="B5" value="35.3" spread="13.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="102"/>
                <measurement group_id="B2" value="99"/>
                <measurement group_id="B3" value="48"/>
                <measurement group_id="B4" value="51"/>
                <measurement group_id="B5" value="300"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="101"/>
                <measurement group_id="B2" value="100"/>
                <measurement group_id="B3" value="49"/>
                <measurement group_id="B4" value="50"/>
                <measurement group_id="B5" value="300"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Characterization and Comparison of the Safety of the TD Vaccine System: (1) Solicited and Unsolicited Adverse Events (AEs) (2) Clinical Laboratory Safety (3) Serious AEs</title>
        <description>Erythema, rash, pain, pruritus, hyperpigmentation, hypopigmentation and edema were solicited local AEs for the duration of the study. Fever, malaise, headache, and diarrhea were solicited systemic AEs for the first seven days following each vaccination; events reported outside this time frame were considered non-solicited.</description>
        <time_frame>Day 0 to Day 180</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group 1 &amp; 2 Combined: 37.5µg LT Patch</title>
            <description>with or without swabbing</description>
          </group>
          <group group_id="O2">
            <title>Group 3 &amp; 4 Combined: Placebo Patch (0µg LT)</title>
            <description>with or without swabbing</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="402"/>
                  <measurement group_id="O2" value="198"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Characterization and Comparison of the Safety of the TD Vaccine System: (1) Solicited and Unsolicited Adverse Events (AEs) (2) Clinical Laboratory Safety (3) Serious AEs</title>
            <description>Erythema, rash, pain, pruritus, hyperpigmentation, hypopigmentation and edema were solicited local AEs for the duration of the study. Fever, malaise, headache, and diarrhea were solicited systemic AEs for the first seven days following each vaccination; events reported outside this time frame were considered non-solicited.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Solicited Local Adverse Events (1st vaccination)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="318"/>
                  <measurement group_id="O2" value="93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Solicited Local AEs (2nd vaccination)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="327"/>
                  <measurement group_id="O2" value="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-solicited Local AEs (1st vaccination)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-solicited Local AEs (2nd vaccination)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Solicited Systemic AEs (overall)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="134"/>
                  <measurement group_id="O2" value="59"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-solicited Systemic AEs (overall; &gt;=2%)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="296"/>
                  <measurement group_id="O2" value="148"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serious AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterization and Comparison of Group LT-specific Immune Responses to the TD Vaccine System: (1) Geometric Mean Titers (2) Geometric Mean Fold Ratios (3) Seroconversion Rates</title>
        <time_frame>Day 0 to Day 180</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1: 37.5μg LT, No Swab</title>
          <description>Two vaccination regimen with an LT patch (no swabbing)
Heat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System</description>
        </group>
        <group group_id="E2">
          <title>Group 2: 37.5μg LT, Swab</title>
          <description>Two vaccination regimen with an LT patch (with swabbing)
Heat-Labile Enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System</description>
        </group>
        <group group_id="E3">
          <title>Group 3: 0μg LT, No Swab</title>
          <description>Two vaccination regimen with a placebo patch (no swabbing)
Placebo: Travelers' Diarrhea Vaccine System</description>
        </group>
        <group group_id="E4">
          <title>Group 4: 0μg LT, Swab</title>
          <description>Two vaccination regimen with a placebo patch (with swabbing)
Placebo: Travelers' Diarrhea Vaccine System</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="192" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="92" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Vaccination site erythema</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Vaccination site rash</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Vaccination site hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Vaccination site edema</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Vaccination site pruritis</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="199"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head Clinical Developement</name_or_title>
      <organization>Valneva Austria GmbH</organization>
      <phone>0043120620 ext 0</phone>
      <email>info@valneva.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
